menu
    • menu
    [{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Audentes Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"scAAV9.U7.ACCA","moa":"Dystrophin exon-51","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Audentes Therapeutics \/ Audentes Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Audentes Therapeutics"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"AT342","moa":"GAA","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Audentes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Audentes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AT845","moa":"Lysosomal alpha-glucosidase (GAA)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":3,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Audentes Therapeutics

    Menu

    Audentes Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resamirigene Bilparvovec

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myo...

                            Details : The company is now working to complete all clinical and regulatory activities necessary to resume dosing and plans to have discussions at a future date with the regulators on the path forward toward global registration filings for AT132.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 25, 2020

                            Lead Product(s) : Resamirigene Bilparvovec

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resamirigene Bilparvovec

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked ...

                            Details : The application was based on the Phase 3 study interim analysis of study participants treated with investigational product manufactured by the to-be-commercialized process and three-year data from the Phase 1/2 Study.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 20, 2020

                            Lead Product(s) : Resamirigene Bilparvovec

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT845

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Audentes is Developing AT845 for the Treatment of Pompe Disease.

                            Details : Audentes is developing AT845, developed to recognise limitations of ERT by facilitating the intracellular production of GAA to improve efficacy, reduce immunogenicity, and deliver a durable and transformative clinical benefit from a single intravenous ad...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 05, 2020

                            Lead Product(s) : AT845

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : scAAV9.U7.ACCA

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Recipient : Megan Waldrop

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.

                            Details : ScAAV9.U7.ACCA is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : scAAV9.U7.ACCA

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Megan Waldrop

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resamirigene Bilparvovec

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $3,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Astellas Completes Acquisition of Audentes Therapeutics

                            Details : Combined company establishes to become a global leader in AAV-based medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $3,000.0 million

                            January 15, 2020

                            Lead Product(s) : Resamirigene Bilparvovec

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $3,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Audentes Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT342

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gene Transfer Clinical Study in Crigler-Najjar Syndrome

                            Details : AT342 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Crigler-Najjar Syndrome.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 21, 2017

                            Lead Product(s) : AT342

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth